Description
SB939 is an inhibitor of class I, II, and IV histone deacetylases (HDACs) that exhibits anticancer chemotherapeutic, anti-parasitic, and antimalarial activities. SB939 decreases tumor growth in animal models of colorectal cancer. This compound also suppresses Plasmodium growth in vitro and in vivo and prevents malaria infection.
References
Zorzi AP, Bernstein M, Samson Y, et al. A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium. Pediatr Blood Cancer. 2013 Nov;60(11):1868-74. PMID: 23893953.
Sumanadasa SD, Goodman CD, Lucke AJ, et al. Antimalarial activity of the anticancer histone deacetylase inhibitor SB939. Antimicrob Agents Chemother. 2012 Jul;56(7):3849-56. PMID: 22508312.
Novotny-Diermayr V, Sangthongpitag K, et al. SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol Cancer Ther. 2010 Mar;9(3):642-52. PMID: 20197387.